What's killing patients in Bayer's Xofigo combo study? Researchers unblind study early to probe safety alert
Back in the spring of 2016, researchers reported that a combination of Bayer’s Xofigo (radium-223) with Zytiga (abiraterone) came through with evidence of significantly reduced bone pain for men suffering from prostate cancer. But scientists were forced to unblind the Phase III pivotal trial prematurely after an independent monitoring group spotted a higher rate of deaths in the treatment arm.
The company, which has been pursuing new cancer drugs as a core approach to pipeline construction, had enrolled 806 patients who either got the combo or just Zytiga, a well established blockbuster that helped change the standard of care in prostate cancer.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.